Solid Biosciences (SLDB) Operating Expenses (2017 - 2026)

Solid Biosciences has disclosed Operating Expenses across 10 years of filings, most recently posting $57.3 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $57.3 million, up 43.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $196.5 million (up 37.46% YoY), and the FY2025 annual result was $179.2 million, up 38.14% from the prior year.
• Operating Expenses came in at $57.3 million for Q1 2026 at Solid Biosciences, up from $49.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $57.3 million in Q1 2026 to a low of $21.1 million in Q3 2022.
• The 5-year median for Operating Expenses is $32.0 million (2023), against an average of $34.4 million.
• Across the five-year window, Operating Expenses tumbled 35.59% in 2023 and jumped 79.19% in 2024, its largest moves.
• Solid Biosciences' Operating Expenses stood at $34.6 million in 2022, then sank by 35.59% to $22.3 million in 2023, then surged by 79.19% to $39.9 million in 2024, then gained by 23.83% to $49.4 million in 2025, then rose by 16.0% to $57.3 million in 2026.
• The last three Operating Expenses figures came in at $57.3 million (Q1 2026), $49.4 million (Q4 2025), and $48.1 million (Q3 2025), per Business Quant data.